SEATTLE, WA – Calypso® Medical announced today that the U.S. Food and Drug Administration (FDA) cleared a new indication for the use of implantable Beacon® electromagnetic transponders with the Calypso System in external beam radiation therapy.
ROCKVILLE, MD — MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the appointments of Dr. Jean-Christophe Tellier as Executive Vice President and Chief Commercial Officer and Mr. James Karrels as Vice President and Chief Financial Officer.
RESEARCH TRIANGLE PARK, NC — Tryton Medical, Inc. announced today that it has appointed J. Greg Davis as President and Chief Executive Officer. Founded in 2003, Tryton Medical is the leading developer of stents that are designed to definitively treat bifurcation lesions.
ST. LOUIS, MO – RiverVest Venture Partners announced today that it has completed fundraising for its second fund, RiverVest Venture Fund II, L.P., with total committed capital of $75 million from private investors. RiverVest’s first fund, which was licensed as a Small Business Investment Company, had total private capital of $45 million,plus one tier of leverage from the Small Business Administration.
NEWTON, MA – Tryton Medical, Inc., the leading developer of stents designed for the definitive treatment of bifurcation lesions announced today that it has closed a $14 million Series C round of financing.
DOVER, NH – TissueLink Medical, Inc., a privately held medical device company, announced today that the Company has changed its name to Salient Surgical Technologies, Inc. The name change is effective today.
Accumetrics, Inc. a privately-held medical device company and maker of the VerifyNow family of tests that measure patient response to antiplatelet drugs, announced today that it has raised $28.8 million in its Series D financing. The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.
ST. LOUIS, MO and CLEVELAND, OH – RiverVest Venture Partners, a life science venture capital firm headquartered in St. Louis, MO, announced today that it will be opening an office at the BioEnterprise facility in Cleveland, OH. The office will be managed by Karen Spilizewski, who is joining RiverVest on a part-time basis as a vice president on January 1, 2008.
Excaliard closes $15.5 million Series A financing from Alta Partners, ProQuest Investments and RiverVest Venture Partners
CARLSBAD, CA and ENCINITAS, CA – Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Excaliard Pharmaceuticals, Inc. announced today a new collaboration to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring.
SEATTLE, WA and SUNNYVALE, CA – Calypso Medical and IMPAC Medical Systems, an Elekta company, have identified product collaboration projects which will further enable integration of oncology management systems with the Calypso® 4D Localization System™.
Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments
INDIANAPOLIS, IN and ROCKVILLE, MD – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. today announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner. Dr. Foulkes brings to RiverVest extensive operational experience in biopharmaceutical research and development.